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The accumulation of genetic alterations in driver genes is responsible for the development and malignant progression of colorec-
tal cancer. Comprehensive genome analyses have revealed the driver genes, including APC, KRAS, TGFBR2, and TP53, whose
mutations are frequently found in human colorectal cancers. Among them, the p53 mutation is found in ∼60% of colorectal can-
cers, and a majority of mutations are missense-type at ‘hot spots’, suggesting an oncogenic role of mutant p53 by ‘gain-of-func-
tion’ mechanisms. Mouse model studies have shown that one of these missense-type mutations, p53 R270H (corresponding to
human R273H), causes submucosal invasion of intestinal tumors, while the loss of wild-type p53 has a limited effect on the inva-
sion process. Furthermore, the same mutant p53 promotes metastasis when combined with Kras activation and TGF-β suppres-
sion. Importantly, either missense-type p53 mutation or loss of wild-type p53 induces NF-κB activation by a variety of
mechanisms, such as increasing promoter accessibility by chromatin remodeling, which may contribute to progression to
epithelial–mesenchymal transition. These results indicate that missense-type p53 mutations together with loss of wild-type p53
accelerate the late stage of colorectal cancer progression through the activation of both oncogenic and inflammatory pathways.
Accordingly, the suppression of the mutant p53 function via the inhibition of nuclear accumulation is expected to be an effective
strategy against malignant progression of colorectal cancer.
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Introduction
It has been suggested that the accumulation of driver gene
mutations causes development and malignant progression of
colorectal cancer. TP53/Trp53 (human or mouse p53 gene)
encoding tumor suppressor p53 is one of the important major
driver genes for cancer development in various organs. In add-
ition to the tumor-suppressing role of p53, it has been shown
that some missense-type mutations of the p53 gene at the DNA
binding domain induce acquisition of oncogenic functions. We
therefore need to consider the role of p53 mutation in colorectal
cancer development from two separate aspects: the ‘loss of
wild-type p53 function’ and the ‘possible gain of oncogenic
function of missense-type mutant p53’.
Recent genetic studies of human cancers as well as mouse
model studies have revealed these complicated roles of p53
mutations in tumorigenesis. We herein review the role of mutant
p53 (missense-type mutant p53 and loss of wild-type p53) high-
lighting what we have learned from human and mouse genetic
studies.
Multistep tumorigenesis of colorectal cancer
Colorectal cancer is the third-most common cancer and a
leading cause of cancer-related death world-wide (Ferlay et al.,
2013; Siegel et al., 2017). The 5-year survival rate drops signifi-
cantly to about 14% for patients with metastasis (Howlader
et al., 2017). It is therefore important to clarify the mechanisms
underlying malignant progression process in order to develop a
novel therapeutic strategy. Colorectal cancer begins as a benign
adenomatous intestinal polyp, which progresses to advanced
adenoma with high-grade dysplasia, invasive adenocarcinoma,
and metastasis to distant organs. The concept of such gradual pro-
gression of colorectal cancer is known as ‘multistep tumorigen-
esis’, and each step is thought to be associated with specific
genetic alterations in tumor suppressors or oncogenes (Fearon and
Vogelstein, 1990; Markowitz and Bertagnolli, 2009; Fearon, 2011).
Recent genome-wide analyses have identified frequently
mutated genes in human colorectal cancers, including APC,
KRAS, SMAD4, and TP53, mutations of which are found in about
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10–80% of non-hypermutated colorectal cancers (The Cancer
Genome Atlas Network, 2012; Giannakis et al., 2016). Genetic
alterations in these genes are thought to cause acquisition of
stemness, increased cell proliferation, suppression of differenti-
ation, and impaired genome DNA maintenance, which may con-
tribute to ‘hallmarks of cancer’ (Hanahan and Weinberg, 2011)
as major components of the cancer cell signaling pathways
(Vogelstein et al., 2013). Furthermore, the modification of these
pathways by the same genetic alterations is widely found in
many types of cancers, suggesting that these are key driver
pathways for oncogenesis, irrespective of tissue type (Sanchez-
Vega et al., 2018).
The development of organoid culture techniques of normal
intestinal stem cells has allowed us to validate the oncogenic
role of driver mutations in vitro (Sato et al., 2009). It has been
genetically demonstrated using human normal intestinal orga-
noids that the simultaneous introduction of mutations in APC,
KRAS, PIK3CA, SMAD4, and TP53, four or five major driver genes
for colorectal cancer, induces epithelial cell transformation
resulting in the development of transplantable tumors in vivo
(Drost et al., 2015; Matano et al., 2015). These genetic experi-
ments using organoids support the concept of multistep tumori-
genesis of colon cancer, although additional epigenetic changes
may be important for achieving a more advanced malignant
phenotype (Matano et al., 2015).
Mutations of TP53 in human colorectal cancer
Germline mutations in TP53 are responsible for Li-Fraumeni
syndrome, a familial cancer syndrome of diverse tumors, indicat-
ing a tumor suppressor role of p53 in a variety of tissues
(Malkin et al., 1990; Srivastava et al., 1990). Consistently, the
most frequently mutated gene in the Pan-Cancer cohort is TP53
(42% of all samples examined) (Kandoth et al., 2013). In non-
hypermutated colorectal cancers, the mutation rate of TP53 is
about 55%–60%, which is the second-most frequent mutation
observed in colorectal cancer (APC mutation is found >80%),
whereas the mutation rate of TP53 is significantly decreased to
∼20% in hypermutated colorectal cancers (The Cancer Genome
Atlas Network, 2012; Kandoth et al., 2013; Giannakis et al.,
2016).
Moreover, TP53 mutations have been associated with a poor
prognosis in several types of cancers, including colorectal can-
cers (Olivier et al., 2010). Consistently, when advanced colorec-
tal cancer patients who suffered metastasis were examined, the
TP53 mutation rate increased to 80% (Brannon et al., 2014). On
the other hand, TP53 mutations are not common in benign
colonic adenomatous polyps (Borras et al., 2016), and its alter-
ation frequencies are about 15%–30% (Baker et al., 1990; Hao
et al., 2002). These results support the hypothesis that TP53
mutations play a role in the late stage of tumorigenesis, such as
progression step of adenomas to invasive adenocarcinomas or
metastasis to distant organs.
Cellular stress, like DNA damage, telomere erosion, hypoxia,
and nutrient depletion, as well as oncogenic signaling, activates
p53, leading to the promotion of cell-cycle arrest, senescence,
and apoptosis depending on the extent and context of the stress
(Vousden and Lu, 2002; Vousden and Prives, 2009). These dis-
tinct stress responses are regulated by subsets of p53 target
molecules, including p21, Puma, Tiger, and PAI-1, which respond
to different p53-activating stimuli (Beckerman and Prives, 2010).
The loss of p53 transcriptional activity that causes the suppres-
sion of these p53 target induction is thought to be a major
mechanism by which TP53 loss-of-function mutations promote
tumorigenesis in various organs including colon.
Missense-type mutant p53 for cancer development
It has been shown that a majority (∼74%) of TP53 somatic
mutations in cancer cells are missense-type mutations with ami-
no acid substitutions in the DNA binding domain. There are sev-
eral ‘hot spot’ residues (R175, G245, R248, R249, R273, and
R282). Since p53 normally functions as a tetramer, such mutant
p53 may inhibit the role of remaining wild-type p53 by a ‘dominant-
negative’ mechanism. It has been shown that the expression of
mutant p53 R172H (corresponding to human R175H) in a mouse
model attenuates the therapeutic effect induced by the restor-
ation of wild-type p53 (Wang et al., 2011). However, accumulat-
ing evidence has shown that TP53 mutations at these hot spots
can induce acquisition of an oncogenic function via a ‘gain-of-
function’ mechanism (Brosh and Rotter, 2009; Muller and
Vousden, 2014), although each mutant p53 can have distinct
effects on tumorigenesis (Mello and Attardi, 2013; Muller and
Vousden, 2014). Moreover, these missense-type TP53 muta-
tions are significantly and positively correlated with a poor
survival in colorectal cancer patients, suggesting a role of
gain-of-function by p53 mutation in malignant progression
step (Cooks et al., 2018). Notably, in the non-hypermutated
human colon cancer, about 80% of tumors that carry missense
mutations lost wild-type TP53 genes via loss of heterozygosity
(LOH) (The Cancer Genome Atlas Network, 2012). Taken together,
these results suggest that the presence of missense-type mutant
p53 at hot spots can promote progression of colon tumors from
adenoma to adenocarcinoma by gain-of-function mechanism,
and the additional loss of wild-type p53 by LOH induces a
more advanced phenotype at a later stage of tumorigenesis.
Mouse model studies have provided genetic evidence of the
gain-of-function mechanism by two major missense-type mutant
p53 in tumorigenesis. Genetically engineered mouse models that
express Trp53 R172H or R270H mutations (corresponding to the
human TP53 R175H or R273H, respectively) developed spontan-
eous adenocarcinomas in the intestine and lung with the nuclear
accumulation of p53, findings not noted in Trp53Null (deleted)
mutant mice (Lang et al., 2004; Olive et al., 2004). Several pos-
sible mechanisms for tumorigenesis by the missense-type mutant
p53 proteins have been reported. For example, mutant p53 pro-
tein drives invasiveness and the scattered migration of cancer
cells by promoting Rub coupling protein (RCP)-recycling of integ-
rin and the receptor for hepatocyte growth factor (HGF), MET,
thereby resulting in the activation of EGFR/integrin and HGF sig-
naling, respectively (Muller et al., 2009, 2013). Furthermore,
mutant p53 promotes cancer metastasis by binding p63 and p73,
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which accelerates TGF-β-induced metastasis and PDGF receptor β
signaling, respectively (Adorno et al., 2009; Weissmueller et al.,
2014). It has also been shown that mutant p53 increases
the stem cell pool of mammary epithelial cells, which causes
increased susceptibility for tumorigenesis (Lu et al., 2013).
Recently, epigenetic mechanisms induced by mutant p53 pro-
tein for tumorigenesis have been demonstrated, which explains
the transcriptional activation of myriad genes, including onco-
genes, by the expression of mutant p53 (Freed-Pastor and
Prives, 2012). Several missense-type mutations of p53, includ-
ing R175H and R273H have shown to induce global transcrip-
tional shift by epigenetic switching of promoters through
interaction with the SWI/SNF chromatin remodeling complex or
the induction of MLL1, MLL2, and MOZ to modify histone methy-
lation and acetylation (Pfister et al., 2015; Prives and Lowe,
2015; Zhu et al., 2015). A mouse model study using ‘sleeping
beauty’ transposon also indicated that the mutation of Arid1a, a
component of SWI/SNF, was enriched by transposons in in vivo
intestinal tumors when the mouse carried heterozygous Trp53
R172H (human R175H) mutation, suggesting an additive effect
of mutations in p53 and the SWI/SNF complex for intestinal
tumorigenesis (Takeda et al., 2015). These results suggest that
the presence of missense-type mutant p53 at hot spots can
induce transcriptome shift via the modification of the chromatin
status of gene promoters in colorectal cancer cells.
Loss of wild-type p53 in intestinal tumor mouse model
APC gene mutation is a gate keeper event for colorectal cancer
development that activates canonical Wnt signaling. In normal
intestinal stem cells, Wnt ligands from stromal cells stimulate
Frizzled receptors, resulting in the destruction of the APC,
β-catenin, and GSK3β complex that is required for β-catenin deg-
radation. Wnt signaling thus induces β-catenin stabilization and
translocation to the nucleus, forming a complex with TCF, and
then β-catenin functions as a transcription factor to induce Wnt-
target genes, which plays an important role in stem cell mainten-
ance (Nusse and Clevers, 2017). Accordingly, the APC mutation
causes intestinal tumorigenesis via the constitutive activation of
Wnt signaling in epithelial cells.
Chemically induced or genetically engineered heterozygous
Apc mutant models (ApcMin and ApcΔ716 mice, respectively)
develop multiple intestinal polyps upon the somatic loss of
wild-type Apc gene by LOH, which results in constitutive Wnt
signaling activation (Moser et al., 1990; Oshima et al., 1995). To
examine the effect of the loss of wild-type p53 on intestinal
tumorigenesis, several compound mutant mice were generated
by crossing (Jackstadt and Sansom, 2016). The introduction of
the Null allele for Trp53 in ApcMin mice did not cause any pro-
gression of intestinal adenomas (Clarke et al., 1995; Fazeli
et al., 1997). These studies used mice with a heterogenous gen-
etic background of C57BL/6 and 129 strains. Interestingly, when
ApcMin Trp53−/− mice were examined with a C57BL/6 inbred
background, local submucosal invasion was found at a low fre-
quency (Halberg et al., 2000). Taken together, these results sug-
gest that the loss of wild-type p53 in the absence of mutant p53
might contribute to the invasion of benign tumors, although it is
not sufficient to drive the process, and modifier gene alteration
depending on genetic background may be required.
Missense-type mutant Trp53 in intestinal tumor mouse model
In contrast to the Null mutation, the introduction of heterozy-
gous mutations of Trp53 R172H or R270H in ApcMin or ApcΔ716
mice, respectively, induced submucosal invasion of intestinal
tumors (Figure 1A) (Muller et al., 2009; Nakayama et al., 2017).
The incidence of invasion was significantly higher in
ApcΔ716Trp53+/R270H mice than in ApcΔ716Trp53Null mice (9% vs.
0% of small tumors <3 mm, and 62% vs. 16% of large tumors
≥3 mm), and high-grade dysplasia was found in the invading
tumors with Trp53 R270H mutations (Nakayama et al., 2017).
As discussed above, the loss of wild-type p53 by LOH in add-
ition to the missense-type mutation is thought to be important
for malignant progression of cancers. However, we noted no loss
of wild-type Trp53 at the invasion front of ApcΔ716Trp53+/R270H
mice. These results suggest that missense-type mutant p53 at
codon R172 and R270 (human codon R175 and R273, respect-
ively) is a key factor inducing submucosal invasion of intestinal
tumors by gain-of-function mechanism, and the loss of wild-type
p53 by LOH may not be required for this process.
The nuclear accumulation of mutant p53 and its possible
regulation mechanism
In ApcΔ716Trp53R270H/R270H mouse intestinal tumors (Trp53
R270H homozygous mutant), the clear nuclear accumulation of
p53 was detected by immunohistochemistry. However, in the
ApcΔ716Trp53+/R270H mice (Trp53+/R270H heterozygous mutant),
p53 was detected but distributed to the cytoplasm (Figure 1B)
(Nakayama et al., 2017). These results suggest that wild-type
p53 interferes with the nuclear accumulation of mutant p53 in
the heterozygous tumor cells.
This hypothesis was further tested in cell culture experiments.
We established a cell line from ApcΔ716Trp53R270H/R270H mouse
intestinal tumors (AP-MM6 cells), which show the clear nuclear
accumulation of mutant p53. Importantly, transfection of wild-
type p53 expression vector to AP-MM6 cells resulted in the par-
tial cytoplasmic distribution of p53 (Figure 1C). We further found
that p53 is clearly accumulated in the nucleus in Trp53R270H/R270H
and Trp53R270H/LOH tumor organoids, while cytoplasmic distribu-
tion was also found in Trp53+/R270H organoid cells (Figure 1D). It
is therefore possible that the chimeric tetramer complex consist-
ing of mutant p53 and wild-type p53 cannot remain in the nuclei
(Figure 2). On the other hand, it has been reported that the loss
of wild-type p53 is an important prerequisite for the stabilization
of mutant p53 in breast cancer and sarcomas, suggesting that
chimeric p53 tetramers are not stable in these cells (Alexandrova
et al., 2017). We have not examined how the chimeric p53 tetra-
mers are stabilized in the cytoplasm of intestinal tumor cells,
however, it is possible that stability of chimeric p53 complex var-
ies according to the tissue type.
Interestingly, it has also been reported that mutant p53 R172H
is stable only in tumor cells but not in normal tissues (Terzian
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et al., 2008). However, we found that p53 R270H proteins are
detected in the tumor cells as well as in the normal intestinal cryp-
tic cells of ApcΔ716Trp53R270H/R270H mice (Figure 1B). Consistently,
p53 R172H is detected in the intestinal crypt of wild-type mice
(Goh et al., 2015). Mutant p53 R172H protein expressed in non-
tumorous cells has been shown to be regulated by Mdm2, an E3
ubiquitin ligase for p53, resulting in degradation through the pro-
teasome pathway in a manner similar to wild-type p53. Thus, sta-
bilization is not a result of mutation and is therefore a
prerequisite for the gain-of-function of missense-type mutant p53.
Intriguingly, we found that p53 is accumulated in the nucleus in
a subset of tumor cells at the invasion front of ApcΔ716Trp53+/R270H
mice (Trp53+/R270H heterozygous mutant) (Nakayama et al., 2017).
Taken together, these findings suggest that the microenvironment
of the invasion front as well as normal intestinal crypts contributes
to the stabilization and nuclear localization of mutant p53 by
exogenous stimulation. These results suggest that missense-type
mutant p53 drives the submucosal invasion of the primary intes-
tinal tumors when the microenvironment supports the nuclear
accumulation of p53, although it still remains to be elucidated
Figure 1 Submucosal invasion and the nuclear accumulation of mutant p53. (A) Submucosal invasion of ApcΔ716Trp53+/R270H (Apc Trp53+/M)
mouse intestinal tumors shown by Masson Trichrome staining. The arrowheads indicate the invasion area (enlarged image at the bottom).
(B) p53 immunohistochemistry of intestinal tumors. The nuclear accumulation is detected in ApcΔ716Trp53R270H/R270H (Apc Trp53M/M, Trp53
homozygous mutant) tumor cells (top left), while it is stabilized but distributed to the cytoplasm in ApcΔ716Trp53+/R270H (Apc Trp53+/M,
Trp53 heterozygous mutant) tumor cells (bottom left). p53 is not detected in ApcΔ716Trp53+/+ tumors (bottom right). Notably, the nuclear
accumulation of mutant p53 R270H is also detected in normal intestinal cryptic cells (top right). (C) p53 is detected in the nuclei of AP-MM6
cells (derived from ApcΔ716Trp53R270H/R270H intestinal tumors) (top). Transfection of wild-type p53 into AP-MM6 cells resulted in partial cyto-
plasmic distribution of p53 (middle, arrowheads; bottom, arrows). (D) Confocal images of immunostaining for p53 (green) and E-cadherin
(red) with DAPI staining (blue) of ApcΔ716KrasG12DTgfbr2−/−Trp53R270H mouse tumor-derived organoids. The Trp53 genotypes of tumor cells
are Trp53+/R270H (left), Trp53R270H/LOH (center), and Trp53R270H/R270H (right). Note that mutant p53 is exclusively detected in nuclei when
wild-type p53 is not expressed (center and right), while it is also partially distributed to the cytoplasm of Trp53 heterozygous tumor cells
(left, arrowheads). (A–C) Modified from Nakayama et al. (2017).
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whether the nuclear accumulation of mutant p53 is indeed
required for malignant progression.
Missense-type mutant p53 for advanced cancer phenotypes
We further examined the biological characteristics of tumor
organoids derived from ApcΔ716Trp53R270H/R270H mice and
ApcΔ716Trp53Null mice. In the homozygous Trp53R270H/R270H
tumor organoids, mutant p53 is constitutively localized in
nuclei, as shown above. The morphology of organoids from
ApcΔ716 mice shows a round cystic structure because of the uni-
formly activated Wnt signaling and lack of a differentiation
gradient (Sato et al., 2011); this phenotype was not changed
when the wild-type p53 was lost. In contrast, Trp53R270H/R270H
homozygous tumor organoids formed a complexed glandular
structure that was strikingly different from the Trp53Null mutant
organoids (Figure 2). This glandular structure of tumor
organoids was associated with the significant increase of Wnt
activation level and acquisition of invasiveness, while
ApcΔ716Trp53Null organoids showed limited invasion ability. It
remains to be investigated whether organoid culture conditions
affect the acquisition of such tumor characteristics; however,
the results suggest that mutant p53 induces undifferentiated
status by Wnt signaling activation. These malignant phenotypes
associated with the expression of mutant p53 R270H were
significantly suppressed by the treatment of organoid cells with
suberoylanilide hydroxamic acid (SAHA), a histone deacetylase
(HDAC) inhibitor that induces the degradation of mutant p53
through the Mdm2-mediated ubiquitin proteasome system (Li
et al., 2011; Alexandrova et al., 2015).
In addition, the subcutaneous transplantation of
ApcΔ716Trp53R270H/R270H tumor-derived organoids caused more
aggressive phenotypes than ApcΔ716Trp53Null tumor-derived
organoid did, such as epithelial–mesenchymal transition (EMT)-
like morphology with increased branching and the generation of
a desmoplastic (fibrotic) microenvironment consisting of acti-
vated myofibroblasts (Figure 2). Increased branching of tumor
glands was also evident in human colon cancers with TP53
mutations around codon 273. It has been suggested that a des-
moplastic microenvironment is important for the induction of
the EMT phenotype of cancer cells (Lambert et al., 2017).
Furthermore, colon cancers with fibrotic stroma are classified as
‘consensus molecular subtypes’ (CMS) type 4, which is asso-
ciated with metastasis and a poor prognosis (Guinney et al.,
2015; Dienstmann et al., 2017). Accordingly, it is possible that
the missense-type mutant p53 promotes malignant progression
of colorectal cancer by the induction of a complex glandular
structure, acquisition of invasiveness, and induction of fibrotic
microenvironment generation (Figure 2).
Figure 2 Possible mechanism by which missense-type mutant p53 affects the malignant progression of colorectal cancer cells (explanation
in counterclockwise). Loss of wild-type p53 may contribute to the nuclear accumulation of mutant p53; mutant p53 activates transcription
factors (TFs), including Wnt/β-catenin and NF-κB, by chromatin remodeling; mutant p53 induces the glandular structure of tumor organoids,
possibly caused by Wnt hyper-activation; mutant p53 induces submucosal invasion, with loss of wild-type p53 not necessary for this pro-
cess; mutant p53 induces the generation of an inflammatory microenvironment via fibrotic reactions, consisting of αSMA-positive myofibro-
blasts, which may be accelerated by loss of wild-type p53 (Modified from Nakayama et al., 2017).
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Combination of mutant p53 with other driver mutations in the
course of multistep tumorigenesis
Recently, colon cancer mouse models that recapitulate gen-
etic alterations of human cancers were constructed by simultan-
eous introduction of Apc mutation, KrasG12D mutation, and
Trp53 loss or Trp53 missense-type mutation in organoid cells
and orthotopic transplantation of these engineered organoids to
mice, thereby causing the development of invasive colonic
adenocarcinoma and lymph node or liver metastasis (O’Rourke
et al., 2017; Roper et al., 2017; Fumagalli et al., 2018).
To further examine the role of missense-type mutant p53 in
combination with other driver mutations, we constructed mouse
models carrying all possible combinations of the driver muta-
tions of ApcΔ716, KrasG12D, Tgfbr2−/−, Trp53+/R270H, and Fbxw7−/−
(Oshima et al., 2015; Nakayama et al., 2017; Sakai et al., 2018).
Among the generated mouse genotypes, double mutations of
ApcΔ716Tgfbr2−/− and ApcΔ716Trp53+/R270H resulted in the devel-
opment of invasive adenocarcinoma in the intestine, suggesting
that Wnt signaling activation in combination with TGF-β suppres-
sion or the expression of mutant p53 R270H induces submucosal
invasion (Figure 3), while ApcΔ716KrasG12D combination is not suf-
ficient for generating an invasive phenotype.
We noted that mutational combinations of ApcΔ716Tgfbr2−/−
and ApcΔ716Trp53+/R270H are not sufficient for generating more
advanced malignant phenotypes. Importantly, an additional
Kras mutation, i.e. combinations of ApcΔ716KrasG12DTgfbr2−/− or
ApcΔ716KrasG12DTrp53+/R270H triple mutations, induced advanced
phenotypes like intravasation to capillary vessels and EMT-like
morphology in the invasion areas (Figure 3). Consistently, trans-
plantation experiments using established tumor organoids indi-
cated that triple mutations of ApcΔ716KrasG12DTgfbr2−/− and
ApcΔ716KrasG12DTrp53+/R270H are minimum cores for liver
metastasis, but other double mutations or even triple mutation
of ApcΔ716Trp53+/R270HTgfbr2−/− are not sufficient for the induc-
tion of metastasis, suggesting that a Kras mutation in addition
to Wnt activation and TGF-β suppression or p53 mutation is crit-
ical for metastasis (Figure 3).
Furthermore, among metastatic tumor organoids, we found
that the rate of multiplicity of metastasis was significantly high-
er in ApcΔ716KrasG12DTgfbr2−/−Trp53+/R270H cells than in triple
mutant organoids, and quintuple ApcΔ716KrasG12DTgfbr2−/−
Trp53+/R270HFbxw7−/− cells showed the highest multiplicity. The
gene expression profiles were also evolutionally changed
accordingly (Supplementary Figure S1). These results suggest
that the expression of mutant p53 and the suppression of the
TGF-β pathway may share oncogenic pathways that induce inva-
sion, EMT, and metastasis; and the combination of missense-type
mutant p53 and TGF-β suppression synergistically accelerates
metastasis when combined with Kras activation and Fbxw7
disruption.
Mutant p53 for inflammatory pathway activation
Accumulating epidemiological and genetic results have sug-
gested that inflammatory responses promote colorectal cancer
development, making this a potential preventive or therapeutic
target (Grivennikov et al., 2010; Wang and Dubois, 2010). In the
tumor microenvironment, macrophages are infiltrated (they are
called ‘tumor-associated macrophages’) and activated, expres-
sing CSF-1 and CCL2, which may promote intravasation and
metastasis (Qian and Pollard, 2010; Kitamura et al., 2015).
Macrophage-expressing cytokines can stimulate tumor cells,
activating the transcription factors NF-κB and Stat3 that link
inflammation and cancer (He and Karin, 2011). In chemically
induced colitis-associated colon cancer models, it has been
Figure 3 Multistep tumorigenesis of colorectal cancer development and malignant progression based on the results of multi-crossing mouse
genetic experiments (Sakai et al., 2018). The expression of missense-type p53 mutation or TGF-β suppression causes submucosal invasion,
and additional Kras mutation activation induces more malignant phenotypes, like EMT and metastasis. The loss of wild-type p53 supports
the later stage of malignant progression. Combinations of four and five driver mutations, including missense-type p53 mutation, are
required for an advanced metastatic ability.
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shown that NF-κB activation in both stromal cells and tumor
cells is important for tumorigenesis (Greten et al., 2004).
Furthermore, NF-κB activation together with Wnt signaling acti-
vation in differentiated epithelial cells has shown to induce
dedifferentiation of intestinal epithelial cells and the acquisition
of stem cell properties (Schwitalla et al., 2013a).
However, the mechanism underlying NF-κB activation in
tumor tissues has not yet been fully elucidated. Several studies,
including one from our group, have shown the possible role of
missense-type mutant p53 in NF-κB activation in intestinal
tumors. Schwitalla et al. (2013b) showed that the loss of wild-
type p53 exacerbated chemically induced colitis-associated
colon tumorigenesis with the induction of EMT phenotypes.
Mechanistically, they found that Trp53 disruption suppresses
the expression of the tight junction molecules occludin and clau-
din, which causes a defect in the barrier function of the epithe-
lia. Subsequently, bacterial products like lipopolysaccharide
may infiltrate into the lamina propria, leading to the activation
of residential macrophages, which can further activate NF-κB in
both tumor cells and stromal cells. It has also been shown that
increased permeabilization of tumor cell junctions results in the
activation of macrophages by bacterial infiltration, which
induces IL-23- and Th17-mediated intestinal tumor growth
(Grivennikov et al., 2012).
Cooks et al. (2013) showed that the expression of mutant p53
R172H is associated with persistent inflammatory responses in
chemically induced ulcerative colitis in mouse model, which
results in increased susceptibility to colitis-associated colon
cancer development. TNF-α signaling activates NF-κB in intes-
tinal epithelia to induce target genes. When mutant p53 is
expressed, NF-κB binding to the target gene promoter is signifi-
cantly prolonged, leading to the persistent induction of inflam-
matory cytokine expression. In human colitis-associated colon
cancers, TP53 mutations are the most common founder muta-
tions and are also found in non-tumorous inflamed mucosa,
possibly caused by reactive oxygen species generation (Hussain
et al., 2000; Leedham et al., 2009; Thorsteinsdottir et al., 2011).
Accordingly, it is possible that the expression of missense-type
mutant p53 in ulcerative colitis is prone to colon cancer devel-
opment through induction of inflammatory responses.
We performed RNA sequencing of tumor organoids from
ApcΔ716Trp53+/+, ApcΔ716Trp53Null, and ApcΔ716Trp53R270H/R270H
mice (Trp53 genotypes are different) and found ∼350 genes
that are specifically upregulated in p53 R270H-expressing
tumors (Nakayama et al., 2017). An ingenuity pathway analysis
using these genes revealed that the Wnt signaling pathway and
NF-κB pathway are significantly activated via a mutant p53
R270H expression-dependent mechanism. We also found that
promoter accessibility is increased significantly in the
ApcΔ716Trp53R270H/R270H tumor cells, suggesting that the chro-
matin structures of gene promoters are opened by mutant p53,
which may result in the wide activation of the Wnt/β-catenin
and NF-κB pathways (Figure 2). The mechanism by which
mutant p53 modifies chromatin is consistent with previous find-
ings (Pfister et al., 2015; Prives and Lowe, 2015; Zhu et al.,
2015). The activation of both the Wnt signaling and NF-κB path-
ways by mutant p53 may cause increased stemness or an undif-
ferentiated status of tumor cells (Schwitalla et al., 2013a)
(Figure 2).
Other mechanisms of mutant p53 for NF-κB activation have
also been reported. For example, mutant p53 activates TNF-α-
induced NF-κB activation in cancer cells by binding to tumor
suppressor DAB2IP (Di Minin et al., 2014). Moreover, colon can-
cer cells expressing mutant p53 selectively shed miR-1246-
enriched exosomes, which reprograms the surrounding macro-
phages to express the immunosuppressive cytokines TGF-β and
IL-10 (Cooks et al., 2018). Taken together, these results suggest
that the expression of missense-type mutant p53 as well as loss
of wild-type p53 play a role in the modulation of the inflamma-
tory and immune microenvironment in cancer tissues through a
variety of mechanisms, which significantly contributes to the
induction of EMT and metastasis of colorectal cancer.
Loss of wild-type Trp53 for malignant progression of intestinal
tumors in the absence of missense-type mutations
As discussed above, loss of wild-type p53 in addition to
missense-type p53 mutation is found in later stages of colon
cancer progression. However, a copy number decrease of TP53
without missense-type mutation was also found in ∼15% of
non-hypermutated colorectal cancer (The Cancer Genome Atlas
Network, 2012), suggesting that the partial suppression of the
wild-type p53 function may contribute to malignant progression
in these patients.
A computational network-based analysis revealed that Notch
activation and deletion of wild-type p53 exert a synergistic
effect on the activation of EMT-like processes of colorectal can-
cer (Chanrion et al., 2014). Although genetic alterations in the
Notch pathway are not common in colorectal cancer, Notch acti-
vation is an important cancer driver pathway (Vogelstein et al.,
2013; Sanchez-Vega et al., 2018). Furthermore, Notch signaling
is activated in colon cancer stem cells, which may be important
for the survival and self-renewal characteristics of tumor cells
(Fre et al., 2009; Sikandar et al., 2010). Mechanistically, Notch
signaling induces the expression of EMT factors, such as Zeb1,
Snail, Slug, and Twist, which is suppressed at the translational
level by microRNAs that are transcriptionally regulated by p53
family genes. Accordingly, wild-type p53 suppresses Notch
activation-associated invasive adenocarcinoma development,
and thus, the loss of wild-type p53 may accelerate Notch-
induced progression to invasive adenocarcinoma with EMT phe-
notypes (Chanrion et al., 2014).
A similar mechanism has been shown in different mouse mod-
el study. BRAF is one of the major driver genes of colorectal can-
cers, and the most frequent somatic mutation is a point
mutation at codon 600 (BRAFV600E), which results in a several
hundred-fold increase in kinase activity compared with wild-
type (Davies et al., 2002). The expression of BrafV637E in mouse
intestinal epithelial cells (corresponding to human BRAFV600E)
induced hyperplasia and adenoma development, and wild-type
p53 was activated in the high-grade dysplastic areas of tumors
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(Rad et al., 2013). Notably, the loss of wild-type p53 in this
model induced invasive adenocarcinoma development and dis-
tant metastasis.
Accordingly, these results suggest that tumor suppressor p53
is activated during malignant progression of colorectal tumori-
genesis, which suppresses Notch activation-induced EMT by
microRNA regulation and BRAF activation-induced malignant
phenotype; thus, the loss of wild-type p53 accelerates malig-
nant progression (Figure 3).
Conclusions and perspective
Recent progress in cancer modeling based on genome infor-
mation and innovative technologies, such as organoid cultures,
have allowed us to generate mouse models that recapitulate
the process of malignant progression and metastasis of human
colorectal cancer. Using these models, it has been shown that
the presence of missense-type mutant p53 at hot spots, such as
p53 R270H (human R273H), plays a role in submucosal inva-
sion, the induction of EMT, and metastasis when combined with
other driver mutations. Although several oncogenic mechanisms
induced by mutant p53 have been reported, changes in the
chromatin structure are possibly important for gain-of-function
mechanism induced by mutant p53 that can induce global tran-
scriptome shift. In colorectal cancer cells, Wnt signaling is acti-
vated by APC mutations, and NF-κB is also activated by the
inflammatory microenvironment. Furthermore, cooperation of
the Wnt signaling and the NF-κB pathways have shown to
induce stemness and tumorigenicity. Thus, the simultaneous
hyperactivation of the Wnt and NF-κB pathways in colorectal
cancer cells caused by changing the chromatin status of the tar-
get gene promoter is one of the important oncogenic mechan-
isms by missense-type mutant p53 (Figure 2). This mechanism
also suggests that the expression of mutant p53 is important for
the tumor-initiating ability of colorectal cancer stem cells.
Importantly, the nuclear accumulation appears to be required
for the oncogenic function of mutant p53. Although loss of wild-
type p53 may cause stabilization of mutant p53, it has also
been shown that even after the loss of wild-type p53, mutant
p53 stabilization and nuclear localization are still regulated by
exogenous signaling. Accordingly, further studies will be
required to understand the mechanism underlying mutant p53
stabilization and subcellular localization by microenvironment-
derived signaling. However, such signaling will be an ideal tar-
get for therapies to prevent colorectal cancer progression.
Supplementary material
Supplementary material is available at Journal of Molecular
Cell Biology online.
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